IR 103

Drug Profile

IR 103

Alternative Names: IR-103; REMUNE + Amplivax combination; RemuneX; Second generation HIV vaccine - Immune Response BioPharma

Latest Information Update: 19 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orchestra Therapeutics
  • Developer Immune Response BioPharma; Orchestra Therapeutics
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown HIV-1 infections

Most Recent Events

  • 03 Dec 2013 Clinical trials in HIV-1 infections in USA (IM)
  • 03 Dec 2013 Immune Response BioPharma plans a phase III trial for HIV-1 infections in the US
  • 09 Oct 2009 DAta clean - Organisations
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top